Authors: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1999; Updated and revised by: Dr Gia Toan Tang, RMO, Townsville University Hospital, Townsville, Australia; A/Prof Rosemary Nixon AM, Dermatologist, Skin Health Institute, Melbourne, Australia. Copy edited by Gus Mitchell. February 2021.
Chilblains are tender and/or itchy bumps on acral sites following exposure to damp, cold, non-freezing conditions causing a localised form of vasculitis. Chilblains are also called pernio or perniosis.
Who gets chilblains?
Chilblains can affect all age groups, but is most common in young to middle-aged adults, with a female predominance. Childhood chilblains are well-described but appear to be uncommon. Primary chilblains are unusual in the elderly and an underlying cause should be looked for.
Risk factors predisposing to the development of chilblains include:
Smoking
Low body mass index and poor nutrition
Occupational hazard for outdoor workers, such as fishermen and farmers
Participation in ice-skating sports
Underlying bone marrow disorders eg, chronic myelomonocytic leukaemia
Chilblains are seen in temperate climates rather than in countries with extreme cold where the air is often dry, and appropriate clothing and living conditions minimise the risk. Late winter and early spring, when it is wet and temperatures are above freezing, are the peak seasons for chilblains.
Chilblains and COVID-19
During the COVID-19 pandemic, many cases of chilblain-like changes on the toes ('COVID-toes') have been reported as a late manifestation in children and young adults after a mild illness suspected of being due to the novel coronavirus SARS-CoV-2; PCR swabs and antibodies for the virus have been mostly (but not always) negative. Many reported patients had no recent exposure to cold, and a robust antiviral interferon response has been postulated to induce changes in the small blood vessels.Histology has been performed on a small number of cases and the changes described have been typical of chilblains, chilblain lupus, or a thrombotic vasculopathy pattern. The association between COVID-19 and chilblains is still being defined. However, the development of chilblain-like lesions in the absence of exposure to damp cold or secondary causes, should be suspected as being related to SARS-CoV-2 infection.
Suspected COVID-19 rash
What causes chilblains?
Cold causes constriction of small arteries and veins but a protective physiological reflex intermittently dilates the blood vessels to prevent skin ischaemia.Persistent or prolonged vasoconstriction due to an abnormal vascular reaction to cold may result in hypoxaemia and inflammation to produce chilblains.
What are the clinical features of chilblains?
Chilblains commonly occur on the fingers, toes, and ears (acral sites). However, chilblains can develop on any areas exposed to chronic cold, such as the thighs/hips of horse riders (‘equestrian panniculitis’). Chilblains develop several hours after exposure to damp cold and last for more than 24 hours.
Chilblains typically present as:
Itch and/or burning pain
Localised swelling
Blanchable red/purple discolouration.
Dermoscopy is not very informative, but examination of the nailfoldcapillaries may be useful if an underlying connective tissue disease is suspected.
What are the complications of chilblains?
Severe chilblains may blister, or become eroded and ulcerated.
How are chilblains diagnosed?
Chilblains are usually diagnosed clinically. Investigations are sometimes required to exclude differential diagnoses or look for causes of secondary chilblains.
Skin biopsy of primary idiopathic chilblains shows a superficial and deep lymphocytic vasculitis, lymphocytes around the eccrine sweat glands, subepidermaloedema, with or without interface changes. [see Perniosis pathology].
The Mayo Clinic has developed diagnostic criteria for chilblains:
Major criterion (required) — localised redness and swelling of acral sites lasting at least 24 hours.
Minor criteria (at least one of the following):
Onset and/or worsening in cooler months
Histopathology consistent with chilblains
Improvement with warming and drying.
Chilblains are classified as idiopathic (primary) if there is no associated cause, and secondary if a cause can be identified.
Investigations for secondary causes of chilblains may include:
Wearing warm, dry clothing during cold weather to protect hands, feet, and ears
Vigorous exercise to keep warm and improve circulation
Keep indoor areas warm and dry
Soaking hands in warm water before exposure
Cessation of smoking and other vasoconstrictors
Topical treatments
Topical nitroglycerine 0.2%
Topical betamethasone valerate 0.1% twice daily — may relieve itch
Systemic treatments
Nifedipine 20–60 mg three times daily — hastens healing time and reduces the risk of relapse
Pentoxifylline
What is the outcome for chilblains?
Chilblains usually resolve spontaneously in 1–3 weeks. However, chilblains can become chronic. Recurrences may occur with subsequent exposures or annually.
Bibliography
Arora JS, Kesler A, Min MS. A global retrospective study identifies higher rates of pernio in individuals with connective tissue disease. J Am Acad Dermatol. 2025;92(3):636-640. Pubmed
Aschoff R, Zimmermann N, Beissert S, Günther C. Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic. Dermatopathology (Basel). 2020;7(3):57–63. doi:10.3390/dermatopathology7030010. PubMed
Baeck M, Herman A. COVID toes: where do we stand with the current evidence?. Int J Infect Dis. 2021;102:53–5. doi:10.1016/j.ijid.2020.10.021. PubMed
Ladha MA, Luca N, Constantinescu C, Naert K, Ramien ML. Approach to chilblains during the COVID-19 pandemic. J Cutan Med Surg. 2020;24(5):504–17. doi:10.1177/1203475420937978. PubMed
Neri I, Virdi A, Corsini I, et al. Major cluster of paediatric 'true' primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown. J Eur Acad Dermatol Venereol. 2020;34(11):2630–5. doi:10.1111/jdv.16751. PubMed
Nyssen A, Benhadou F, Magnée M, André J, Koopmansch C, Wautrecht JC. Chilblains. Vasa. 2020;49(2):133–40. doi:10.1024/0301-1526/a000838. PubMed
Singh H, Kaur H, Singh K, Sen CK. Cutaneous manifestations of COVID-19: a systematic review. Adv Wound Care (New Rochelle). 2021;10(2):51–80. doi:10.1089/wound.2020.1309. PubMed
Smith ML. Environmental and sports-related skin diseases. In: Bolognia JL, Schaffer JV, Cerroni L (eds). Dermatology [2 volumes], 4th edn. Elsevier, 2017: 1569–94.
Sohier P, Matar S, Meritet JF, Laurent-Roussel S, Dupin N, Aractingi S. Histopathological features of chilblain-like lesions developing in the setting of the COVID-19 pandemic. Arch Pathol Lab Med. 2020;10.5858/arpa.2020-0613-SA. doi:10.5858/arpa.2020-0613-SA. PubMed